Litigation Details for BRISTOL-MYERS SQUIBB COMPANY v. DOLL (D.D.C. 2009)

BRISTOL-MYERS SQUIBB COMPANY v. DOLL (D.D.C. 2009)

Docket		Date Filed	2009-07-17
Court	District Court, District of Columbia	Date Terminated	2012-01-30
Cause	35:145 Patent Infringement	Assigned To	Emmet G. Sullivan
Jury Demand	None	Referred To
Parties	JOHN J. DOLL
Patents	7,491,725
Attorneys	Randolph D. Moss
Firms	Randolph D. Moss
Link to Docket	External link to docket

Details for BRISTOL-MYERS SQUIBB COMPANY v. DOLL (D.D.C. 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-07-17				External link to document

Bristol-Myers Squibb Company v. Doll, 1:09-cv-01330: Litigation Summary and Patent-Term Analysis

Last updated: August 15, 2026

Bristol-Myers Squibb Company v. Doll, No. 1:09-cv-01330, was a federal action against the U.S. Patent and Trademark Office concerning patent-term adjustment. The case was not a Hatch-Waxman infringement action against a generic drugmaker. It did not involve a Paragraph IV certification, an Orange Book-listed patent dispute, or a biosimilar challenge.

The central issue was whether the USPTO correctly calculated additional patent term under 35 U.S.C. § 154(b), particularly where different categories of USPTO delay overlapped. The case belongs to the same group of patent-term-adjustment disputes affected by the Federal Circuit’s decision in Wyeth v. Kappos. [1][2]

What was Bristol-Myers Squibb v. Doll about?

The case concerned BMS’s challenge to the USPTO’s calculation of patent-term adjustment for a BMS patent or patent application. BMS sued John J. Doll in his official capacity as Acting Director of the USPTO. The action was filed in the U.S. District Court for the District of Columbia under docket number 1:09-cv-01330. [1]

Item	Case information
Plaintiff	Bristol-Myers Squibb Company
Defendant	John J. Doll, Acting Director of the USPTO
Court	U.S. District Court for the District of Columbia
Civil action	No. 1:09-cv-01330
Filing year	2009
Case type	Administrative review of patent-term adjustment
Governing statute	35 U.S.C. § 154(b)
Generic defendant	None
Biosimilar defendant	None
Paragraph IV dispute	No
Orange Book infringement action	No

The dispute was directed at the USPTO’s administrative determination, not at a commercial competitor. BMS sought judicial review under the Administrative Procedure Act and the patent statute’s judicial-review framework. The practical objective was to obtain additional enforceable patent life.

How does patent-term adjustment work under 35 U.S.C. § 154(b)?

Patent-term adjustment compensates patentees for certain USPTO delays during prosecution. Section 154(b) contains three principal categories:

1. “A delay,” covering failures by the USPTO to meet specified examination and processing deadlines.
2. “B delay,” covering failure to issue a patent within three years after the relevant filing date, subject to statutory exclusions.
3. “C delay,” covering delays resulting from appellate review, secrecy orders, and certain interference proceedings.

The statute also provides that the adjustment period must be reduced by periods during which the applicant failed to engage in reasonable efforts to conclude prosecution. It contains an overlap provision limiting recovery where multiple statutory delay periods cover the same period. [2]

The dispute in BMS’s case arose from the interpretation and application of these overlapping provisions. The USPTO had historically calculated the adjustment by treating certain A-delay and B-delay periods as overlapping. That approach produced a shorter adjustment than a calculation that credited each qualifying period until the periods actually overlapped.

What legal issue did Bristol-Myers Squibb raise?

BMS challenged the USPTO’s interpretation of the overlap provision in Section 154(b)(2)(A). The legal question was whether the USPTO could subtract one category of delay from another merely because both periods were associated with the same prosecution interval, or whether the statute required subtraction only when the delays occurred during the same calendar days.

The dispute had commercial significance because each additional day of patent-term adjustment could delay generic competition. For a high-revenue pharmaceutical product, the value of a single day of exclusivity can be substantial.

The USPTO’s position was that certain statutory delay periods should be offset when they arose from the same prosecution activity. Patent owners argued that the statute required a narrower, calendar-based overlap analysis.

How did Wyeth v. Kappos affect the BMS litigation?

The Federal Circuit’s decision in Wyeth v. Kappos rejected the USPTO’s interpretation of the overlap provision. The court held that the USPTO’s interpretation was not entitled to deference and that the agency had improperly reduced patent-term adjustment by treating distinct delay categories as overlapping when the statutory periods did not actually overlap. [3]

Wyeth established a more favorable calculation method for many patent owners:

Issue	USPTO approach before Wyeth	Federal Circuit approach in Wyeth
A-delay and B-delay calculation	Broad administrative overlap	Actual temporal overlap
Additional patent term	Often reduced	Potentially increased
Judicial review	Agency interpretation given practical weight	USPTO interpretation rejected
Business impact	Earlier patent expiration	Later patent expiration

Wyeth was decided in January 2010, while BMS’s action was pending. The decision materially changed the legal landscape for BMS and other patentees with similar patent-term calculations.

What was the procedural status of Bristol-Myers Squibb v. Doll?

The case was filed in the District of Columbia in 2009 as a direct challenge to the USPTO’s patent-term-adjustment determination. The defendant’s name reflected John Doll’s position as Acting Director at the time of filing. David Kappos later became USPTO Director, which explains why related decisions and docket references may identify the defendant as Kappos rather than Doll.

The case should be analyzed with the distinction between the named defendant and the underlying agency action. The defendant was sued in an official capacity. The dispute was therefore against the USPTO’s calculation and interpretation, not against Doll personally.

The Federal Circuit’s ruling in Wyeth became the controlling authority for the statutory interpretation at issue. That decision substantially reduced the need for separate merits analysis of the USPTO’s former methodology in pending patent-term-adjustment cases.

Did the case involve a Paragraph IV certification or generic launch?

No. Bristol-Myers Squibb v. Doll was not a Hatch-Waxman action under 21 U.S.C. § 271(e)(2).

There was:

• No abbreviated new drug application filer as a defendant.
• No Paragraph IV notice letter.
• No claim for patent infringement based on a proposed generic product.
• No 30-month stay.
• No generic launch date established by the litigation.
• No settlement agreement between BMS and a generic manufacturer.

The case’s commercial effect was indirect. A successful patent-term-adjustment challenge could extend the life of a BMS patent, but the docket itself did not resolve whether a particular generic product infringed or whether a generic applicant could launch.

What was the Orange Book status of the patents at issue?

The case was not an Orange Book listing dispute. Section 154(b) patent-term adjustment is distinct from patent-term extension under 35 U.S.C. § 156 and from Orange Book certification procedures under the Hatch-Waxman Act.

Regulatory issue	Relevance to BMS v. Doll
Orange Book listing	Not the subject of the action
Paragraph IV certification	Not present
Section 156 patent-term extension	Not the central legal issue
Section 154(b) patent-term adjustment	Central issue
FDA approval challenge	None
Generic approval litigation	None

A patent could have commercial relevance to an FDA-approved product without the particular USPTO action becoming an Orange Book infringement case. The docket must therefore not be characterized as a direct pharmaceutical product litigation matter.

Did Bristol-Myers Squibb obtain additional patent life?

The legal framework established by Wyeth improved BMS’s position by invalidating the USPTO’s broad overlap methodology. That did not automatically establish a specific number of additional days for every BMS patent. The adjustment had to be recalculated based on the prosecution history, the applicable A, B, and C delay periods, applicant-caused delay, and the actual dates on which the periods overlapped.

A reliable expiration-date analysis requires the patent number, issue date, filing history, PTA certificate, and any terminal disclaimer. The civil-action docket alone does not provide a dependable product-level expiration date. Patent-term adjustment also does not necessarily equal the full amount sought by the patentee.

How strong was the BMS patent position after Wyeth?

BMS’s legal position on the statutory interpretation was materially strengthened. The Federal Circuit’s decision supplied binding authority against the USPTO’s earlier calculation method. The strength of the resulting patent estate depended on separate factors:

Patent-term strength

A patent with substantial non-overlapping A and B delays could receive meaningful additional term after recalculation. A patent with extensive applicant delay, terminal disclaimer restrictions, or prosecution periods that actually overlapped would receive less benefit.

Claim strength

The case did not adjudicate claim construction, validity, written description, enablement, obviousness, or infringement. It therefore provides no direct evidence regarding the technical strength of BMS’s claims.

Manufacturing and formulation protection

The action did not resolve whether BMS had enforceable formulation, polymorph, salt, dosage-form, manufacturing-process, or method-of-use patents. Those protections require separate patent-by-patent analysis.

Geographic coverage

The dispute concerned U.S. patent-term calculation. It did not determine patent rights in Europe, Canada, Japan, China, or other jurisdictions.

What generic-entry risks existed after the litigation?

The case increased the possibility that a BMS patent could remain enforceable longer than the USPTO originally calculated. That could affect the timing of an ANDA applicant’s Paragraph IV strategy, but the case itself did not determine generic entry.

Potential commercial scenarios included:

Scenario	Effect
USPTO recalculation grants additional PTA	Later patent expiration
No material recalculation	Original expiration date remains commercially relevant
Separate patent remains valid	Generic entry may still be delayed
Patent claims are invalidated elsewhere	PTA has reduced practical value
Settlement with a generic company	Entry date governed by settlement terms
No generic litigation	No court-established launch date

The practical value of the case depended on whether the affected patent covered a marketed product and whether other patents independently protected the product.

What licensing or settlement agreements were disclosed?

The case was an administrative patent-term-adjustment dispute between BMS and the USPTO. It was not a licensing dispute, and no BMS-generic settlement was established by the litigation record identified for this docket.

The absence of a generic defendant means the case did not produce a reverse-payment analysis, launch-license date, authorized-generic commitment, or supply arrangement.

Why does the case matter for pharmaceutical patent analysis?

Bristol-Myers Squibb v. Doll is important as part of the broader patent-term-adjustment litigation that culminated in Wyeth. Its principal significance is methodological:

• Patent owners could challenge the USPTO’s overlap calculations.
• A successful challenge could add enforceable days to a patent term.
• The economic impact could be material for products facing generic competition.
• The action did not itself establish infringement, validity, FDA exclusivity, or a launch date.
• Product-level conclusions require review of the underlying patent and prosecution record.

Key Takeaways

• BMS v. Doll, No. 1:09-cv-01330, was a District of Columbia action against the USPTO.
• The case concerned patent-term adjustment under 35 U.S.C. § 154(b).
• It was not a Paragraph IV, Orange Book, biosimilar, or generic-infringement case.
• The Federal Circuit’s Wyeth decision rejected the USPTO’s broad overlap calculation.
• Wyeth strengthened BMS’s position on the governing legal methodology.
• The docket does not by itself establish a product-specific expiration date, additional PTA days, generic launch date, or settlement.
• Formulation, method-of-use, manufacturing, and other patent protections were not adjudicated in this action.
• The case’s commercial importance depended on the identity of the affected patent and the product, if any, covered by that patent.

FAQs About Bristol-Myers Squibb v. Doll

Was Bristol-Myers Squibb v. Doll a patent infringement case?

No. It was an administrative challenge to the USPTO’s patent-term-adjustment calculation.

Did the case involve Bristol-Myers Squibb and a generic manufacturer?

No. The defendant was the USPTO official John J. Doll, not an ANDA filer or pharmaceutical competitor.

What Supreme Court or Federal Circuit case controls the overlap issue?

Wyeth v. Kappos, 591 F.3d 1364 (Fed. Cir. 2010), rejected the USPTO’s broad interpretation of overlapping patent-term-adjustment delays.

Does the case establish the expiration date of a BMS drug patent?

No. A patent number and prosecution record are required to calculate the enforceable expiration date accurately.

Did the litigation create an FDA exclusivity period?

No. FDA regulatory exclusivity and patent-term adjustment are separate legal mechanisms. The case did not grant new orphan-drug, new-chemical-entity, pediatric, or biologic exclusivity.

References

1. Bristol-Myers Squibb Co. v. Doll, No. 1:09-cv-01330, U.S. District Court for the District of Columbia, docket record (2009-2010).

2. Patent Act, 35 U.S.C. § 154(b) (2023).

3. Wyeth v. Kappos, 591 F.3d 1364 (Fed. Cir. 2010).

4. Administrative Procedure Act, 5 U.S.C. §§ 701-706 (2023).

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j) (2023).